litlas
Log inCreate account

Aung Naing

Active 2009–2025

159
Papers
21,276
Citations
76
h-index
143
i10-index

Citations

Citations per year for Aung Naing1997: 1 citations2001: 1 citations2003: 1 citations2004: 2 citations2010: 3 citations2011: 28 citations2012: 75 citations2013: 126 citations2014: 136 citations2015: 171 citations2016: 163 citations2017: 179 citations2018: 243 citations2019: 786 citations2020: 993 citations2021: 1,156 citations2022: 1,122 citations2023: 930 citations2024: 1,537 citations2025: 898 citations2026: 29 citations1998–2000: no citations, so these years are not shown2002: no citations, so this year is not shown2005–2009: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 3,264 citing papers, 27.6% of this breakdownChina: 1,677 citing papers, 14.2% of this breakdownItaly: 695 citing papers, 5.9% of this breakdownGermany: 512 citing papers, 4.3% of this breakdownFrance: 498 citing papers, 4.2% of this breakdownUnited Kingdom: 492 citing papers, 4.2% of this breakdownJapan: 424 citing papers, 3.6% of this breakdownCanada: 382 citing papers, 3.2% of this breakdownSpain: 370 citing papers, 3.1% of this breakdownAustralia: 301 citing papers, 2.6% of this breakdownNetherlands: 301 citing papers, 2.6% of this breakdownSwitzerland: 251 citing papers, 2.1% of this breakdown
0%27.6%Other 22.4%

Institutions

Fields

  • Medicine62.9%
  • Biochemistry, Genetics and Molecular Biology24.3%
  • Immunology and Microbiology7.8%
  • Neuroscience1.1%
  • Engineering1%
  • Pharmacology, Toxicology and Pharmaceutics0.6%
  • Other2.3%

Topics

  • Cancer Immunotherapy and Biomarkers13%
  • CAR-T cell therapy research4.3%
  • Immunotherapy and Immune Responses4%
  • Cancer Genomics and Diagnostics2.9%
  • Immune Cell Function and Interaction2.5%
  • Lung Cancer Treatments and Mutations2.4%
  • Other70.9%

Coauthors

All papers

Open in search
  1. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update

    Authors: Bryan J. Schneider, Jarushka Naidoo, Bianca D. Santomasso, Christina Lacchetti, Sherry Adkins, Milan Anadkat, Michael B. Atkins, Kelly J. Brassil, Jeffrey M. Caterino, Ian Chau, Marianne J. Davies, Marc S. Ernstoff, Leslie Fecher, Monalisa Ghosh, Ishmael Jaiyesimi, Jennifer S. Mammen, Aung Naing, Loretta J. Nastoupil, Tanyanika Phillips, Laura D. Porter, Cristina A. Reichner, Carole Seigel, Jung-Min Song, Alexander Spira, Maria Suarez-Almazor, Umang Swami, John A. Thompson, Praveen Vikas, Yinghong Wang, Jeffrey S. Weber, Pauline Funchain, Kathryn Bollin - Journal of Clinical Oncology 2021 cited by 1,964

  2. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline

    Authors: Julie R. Brahmer, Christina Lacchetti, Bryan J. Schneider, Michael B. Atkins, Kelly Brassil, Jeffrey M. Caterino, Ian Chau, Marc S. Ernstoff, Jennifer M. Gardner, Pamela Ginex, Sigrun Hallmeyer, Jennifer Holter Chakrabarty, Natasha B. Leighl, Jennifer S. Mammen, David F. McDermott, Aung Naing, Loretta J. Nastoupil, Tanyanika Phillips, Laura Porter, Igor Puzanov, Cristina Reichner, Bianca Santomasso, Carole Seigel, Alexander I. Spira, María E. Suarez‐Almazor, Yinghong Wang, Jeffrey S. Weber, Jedd D. Wolchok, John A. Thompson - Journal of Clinical Oncology 2018 cited by 3,697

  3. A Phase Ib Trial of Personalized Neoantigen Therapy Plus Anti-PD-1 in Patients with Advanced Melanoma, Non-small Cell Lung Cancer, or Bladder Cancer

    Authors: Patrick A. Ott, Siwen Hu‐Lieskovan, Bartosz Chmielowski, Ramaswamy Govindan, Aung Naing, Nina Bhardwaj, Kim Margolin, Mark M. Awad, Matthew D. Hellmann, Jessica J. Lin, Terence W. Friedlander, Meghan E. Bushway, Kristen N. Balogh, Tracey Sciuto, Victoria Kohler, Samantha Jane Turnbull, Rana H. Besada, Riley R. Curran, Benjamin Trapp, Julian Scherer, Asaf Poran, Dewi Harjanto, Dominik Barthelme, Ying S. Ting, Jesse Z. Dong, Yvonne Ware, Yu-Ting Huang, Zhengping Huang, Amy Wanamaker, Lisa D. Cleary, Melissa A. Moles, Kelledy Manson, Joel Greshock, Zakaria Khondker, Ed Fritsch, Michael S. Rooney, Mark DeMario, Richard B. Gaynor, Lakshmi Srinivasan - Cell 2020 cited by 763

  4. Complex I inhibitor of oxidative phosphorylation in advanced solid tumors and acute myeloid leukemia: phase I trials

    Authors: Timothy A. Yap, Naval Daver, Mikhila Mahendra, Jixiang Zhang, Carlos Kamiya-Matsuoka, Funda Meric‐Bernstam, Hagop M. Kantarjian, Farhad Ravandi, Meghan Collins, Maria Emilia Di Francesco, Ecaterina E. Dumbrava, Siqing Fu, Sisi Gao, Jason Gay, Sonal Gera, Jing Han, David S. Hong, Elias Jabbour, Zhenlin Ju, Daniel D. Karp, Alessia Lodi, Jennifer R. Molina, Natalia Baran, Aung Naing, Maro Ohanian, Shubham Pant, Naveen Pemmaraju, Prithviraj Bose, Sarina A. Piha‐Paul, Jordi Rodón, Carolina Salguero, Koji Sasaki, Anand Kumar Singh, Vivek Subbiah, Apostolia M. Tsimberidou, Quanyun A. Xu, Musa Yılmaz, Qi Zhang, Yuan Li, Christopher A. Bristow, Meenakshi B. Bhattacharjee, Stefano Tiziani, Timothy P. Heffernan, Christopher P. Vellano, Philip Jones, Cobi J. Heijnen, Annemieke Kavelaars, Joseph R. Marszalek, Marina Konopleva - Nature Medicine 2023 cited by 377

  5. Phase I/Ib Clinical Trial of Sabatolimab, an Anti–TIM-3 Antibody, Alone and in Combination with Spartalizumab, an Anti–PD-1 Antibody, in Advanced Solid Tumors

    Authors: Giuseppe Curigliano, Hans Gelderblom, Nicolas Mach, Toshihiko Doi, David Tai, Patrick M. Forde, John Sarantopoulos, Philippe L. Bédard, Chia‐Chi Lin, F. Stephen Hodi, Sofie Wilgenhof, Armando Santoro, Catherine Sabatos-Peyton, Tyler A. Longmire, Alexandros Xyrafas, Haiying Sun, Sabine Gutzwiller, Luigi Manenti, Aung Naing - Clinical Cancer Research 2021 cited by 348

  6. Management of Immune-Related Adverse Events in Patients Treated With Chimeric Antigen Receptor T-Cell Therapy: ASCO Guideline

    Authors: Bianca D. Santomasso, Loretta J. Nastoupil, Sherry Adkins, Christina Lacchetti, Bryan J. Schneider, Milan Anadkat, Michael B. Atkins, Kelly J. Brassil, Jeffrey M. Caterino, Ian Chau, Marianne J. Davies, Marc S. Ernstoff, Leslie Fecher, Pauline Funchain, Ishmael Jaiyesimi, Jennifer S. Mammen, Jarushka Naidoo, Aung Naing, Tanyanika Phillips, Laura D. Porter, Cristina A. Reichner, Carole Seigel, Jung-Min Song, Alexander Spira, Maria Suarez-Almazor, Umang Swami, John A. Thompson, Praveen Vikas, Yinghong Wang, Jeffrey S. Weber, Kathryn Bollin, Monalisa Ghosh - Journal of Clinical Oncology 2021 cited by 376

  7. Applications and clinical trial landscape using Toll-like receptor agonists to reduce the toll of cancer

    Authors: Christian Rolfo, Elisa Giovannetti, Pablo Martínez, Shannon McCue, Aung Naing - npj Precision Oncology 2023 cited by 147

  8. Next steps for clinical translation of adenosine pathway inhibition in cancer immunotherapy

    Authors: Ryan C. Augustin, Robert D. Leone, Aung Naing, Lawrence Fong, Riyue Bao, Jason J. Luke - Journal for ImmunoTherapy of Cancer 2022 cited by 124

  9. Probody Therapeutics: An Emerging Class of Therapies Designed to Enhance On-Target Effects with Reduced Off-Tumor Toxicity for Use in Immuno-Oncology

    Authors: Karen A. Autio, Valentina Boni, Rachel Humphrey, Aung Naing - Clinical Cancer Research 2019 cited by 177

  10. PEGylated IL-10 (Pegilodecakin) Induces Systemic Immune Activation, CD8+ T Cell Invigoration and Polyclonal T Cell Expansion in Cancer Patients

    Authors: Aung Naing, Jeffrey R. Infante, Kyriakos P. Papadopoulos, Ivan H. Chan, Cong Shen, Navneet Ratti, Bianca Rojo, Karen A. Autio, Deborah J. Wong, Manish R. Patel, Patrick A. Ott, Gerald S. Falchook, Shubham Pant, Annie Hung, Kara Pekarek, Victoria H. Wu, Matthew Adamow, Scott McCauley, John B. Mumm, Phillip Wong, Peter Van Vlasselaer, Joseph A. Leveque, Nizar M. Tannir, Martin Oft - Cancer Cell 2018 cited by 251

  11. Interleukin-10 in cancer immunotherapy: from bench to bedside

    Authors: Mohamad A. Salkeni, Aung Naing - Trends in cancer 2023 cited by 104

  12. Distinct molecular and immune hallmarks of inflammatory arthritis induced by immune checkpoint inhibitors for cancer therapy

    Authors: Sang T. Kim, Yanshuo Chu, Mercy Misoi, María E. Suarez‐Almazor, Jean Tayar, Huifang Lu, Maryam Buni, Jordan J. Kramer, Emma Rodrı́guez, Zulekha Hussain, Sattva S. Neelapu, Jennifer Wang, Amishi Y. Shah, Nizar M. Tannir, Matthew T. Campbell, Don L. Gibbons, Tina Cascone, Charles Lu, George R. Blumenschein, Mehmet Altan, Bora Lim, V. Valero, Monica Loghin, Janet Tu, Shannon N. Westin, Aung Naing, Guillermo Garcia‐Manero, Noha Abdel‐Wahab, Hussein A. Tawbi, Patrick Hwu, Isabella C. Glitza Oliva, Michael A. Davies, Sapna P. Patel, Jun Zou, P. Andrew Futreal, Adi Diab, Linghua Wang, Roza Nurieva - Nature Communications 2022 cited by 116

  13. Extracellular vesicle PD-L1 dynamics predict durable response to immune-checkpoint inhibitors and survival in patients with non-small cell lung cancer

    Authors: Diego de Miguel‐Pérez, Alessandro Russo, Óscar Arrieta, Murat Ak, Feliciano Barrón, Muthukumar Gunasekaran, Priyadarshini Mamindla, Luis Lara‐Mejía, Christine B. Peterson, Mehmet Emin Er, Vishal Peddagangireddy, Francesco Buemi, Brandon Cooper, Paolo Manca, Rena G. Lapidus, Ru‐ching Hsia, Andrés F. Cardona, Aung Naing, Sunjay Kaushal, Fred R. Hirsch, Philip C. Mack, María José Serrano, Vincenzo Adamo, Rivka R. Colen, Christian Rolfo - Journal of Experimental & Clinical Cancer Research 2022 cited by 106

  14. T-cell agonists in cancer immunotherapy

    Authors: Yeonjoo Choi, Yaoyao Shi, Cara Haymaker, Aung Naing, Gennaro Ciliberto, Joud Hajjar - Journal for ImmunoTherapy of Cancer 2020 cited by 121

  15. A Phase I First-in-Human Trial of Bardoxolone Methyl in Patients with Advanced Solid Tumors and Lymphomas

    Authors: David S. Hong, Razelle Kurzrock, Jeffrey G. Supko, Xiaoying He, Aung Naing, Jennifer J. Wheler, Donald P. Lawrence, Joseph P. Eder, Colin J. Meyer, Deborah A. Ferguson, James W. Mier, Marina Konopleva, Sergej Konoplev, Michael Andreeff, Donald Küfe, Hillard Lazarus, Geoffrey I. Shapiro, Bruce J. Dezube - Clinical Cancer Research 2012 cited by 232

  16. Targeting the indoleamine 2,3-dioxygenase pathway in cancer

    Authors: Yong Wha Moon, Joud Hajjar, Patrick Hwu, Aung Naing - Journal for ImmunoTherapy of Cancer 2015 cited by 333

  17. Influence of injection technique, drug formulation and tumor microenvironment on intratumoral immunotherapy delivery and efficacy

    Authors: Nina M. Muñoz, Malea Williams, K. Dixon, Crystal Dupuis, Amanda McWatters, Rony Avritscher, Soraya Zorro Manrique, Kevin J. McHugh, Ravi Murthy, Alda L. Tam, Aung Naing, Sapna P. Patel, David G. Leach, Jeffrey D. Hartgerink, Simon Young, Punit Prakash, Patrick Hwu, Rahul A. Sheth - Journal for ImmunoTherapy of Cancer 2021 cited by 130

  18. Phase II Trial of Ipilimumab with Stereotactic Radiation Therapy for Metastatic Disease: Outcomes, Toxicities, and Low-Dose Radiation–Related Abscopal Responses

    Authors: James W. Welsh, Chad Tang, Patricia M. de Groot, Aung Naing, Kenneth R. Hess, John V. Heymach, Vassiliki A. Papadimitrakopoulou, Taylor R. Cushman, Vivek Subbiah, Joe Y. Chang, George R. Simon, Rishab Ramapriyan, Hampartsoum B. Barsoumian, Hari Menon, María Angélica Cortez, Erminia Massarelli, Quynh Nguyen, Padmanee Sharma, James P. Allison, Adi Diab, Vivek Verma, Uma Raju, S. Shaaban, Ramona Dadu, Maria E. Cabanillas, Kelvin Wang, Clark Anderson, Daniel R. Gomez, Stephen M. Hahn, Ritsuko Komaki, David S. Hong - Cancer Immunology Research 2019 cited by 146

  19. Targeted methylation sequencing of plasma cell-free DNA for cancer detection and classification

    Authors: L. Liu, Jonathan Toung, Adam Jassowicz, Raakhee Vijayaraghavan, Hee Jung Kang, Ruoyu Zhang, Kristina M. Kruglyak, Helen J. Huang, Toshinori Hinoue, Hui Shen, Neeraj Salathia, David S. Hong, Aung Naing, Vivek Subbiah, Sarina A. Piha‐Paul, Marina Bibikova, Gale A. Granger, Bret Barnes, Richard Shen, Karen Gutekunst, Siqing Fu, Apostolia M. Tsimberidou, Charles Lu, Cathy Eng, Stacy Moulder, Scott Kopetz, R. Amaria, Funda Meric‐Bernstam, Peter W. Laird, Jian‐Bing Fan, F. Janku - Annals of Oncology 2018 cited by 156

  20. Pegilodecakin combined with pembrolizumab or nivolumab for patients with advanced solid tumours (IVY): a multicentre, multicohort, open-label, phase 1b trial

    Authors: Aung Naing, Deborah J. Wong, Jeffrey R. Infante, W. Michael Korn, Raid Aljumaily, Kyriakos P. Papadopoulos, Karen A. Autio, Shubham Pant, Todd M. Bauer, Alexandra Drakaki, Naval Daver, Annie Hung, Navneet Ratti, Scott McCauley, Peter Van Vlasselaer, Rakesh Verma, David Ferry, Martin Oft, Adi Diab, Edward B. Garon, Nizar M. Tannir - The Lancet Oncology 2019 cited by 119

  21. Liquid Biopsies Using Plasma Exosomal Nucleic Acids and Plasma Cell-Free DNA Compared with Clinical Outcomes of Patients with Advanced Cancers

    Authors: Lino Möhrmann, Helen J. Huang, David S. Hong, Apostolia M. Tsimberidou, Siqing Fu, Sarina A. Piha‐Paul, Vivek Subbiah, Daniel D. Karp, Aung Naing, Anne Krug, Daniel Enderle, Tina Priewasser, Mikkel Noerholm, Erez Eitan, Christine M. Coticchia, Georg Stoll, Lisa-Marie Jordan, Cathy Eng, Scott Kopetz, Johan Skog, Funda Meric‐Bernstam, Filip Jankú - Clinical Cancer Research 2017 cited by 164

  22. Safety, Antitumor Activity, and Immune Activation of Pegylated Recombinant Human Interleukin-10 (AM0010) in Patients With Advanced Solid Tumors

    Authors: Aung Naing, Kyriakos P. Papadopoulos, Karen A. Autio, Patrick A. Ott, Manish R. Patel, Deborah J. Wong, Gerald S. Falchook, Shubham Pant, Melinda Whiteside, Drew Rasco, John B. Mumm, Ivan H. Chan, Johanna C. Bendell, Todd M. Bauer, Rivka R. Colen, David S. Hong, Peter Van Vlasselaer, Nizar M. Tannir, Martin Oft, Jeffrey R. Infante - Journal of Clinical Oncology 2016 cited by 217

  23. Strategies for improving the management of immune-related adverse events

    Authors: Aung Naing, Joud Hajjar, James L. Gulley, Michael B. Atkins, Gennaro Ciliberto, Funda Meric‐Bernstam, Patrick Hwu - Journal for ImmunoTherapy of Cancer 2020 cited by 96

  24. Longitudinal Monitoring of Circulating Tumor DNA to Predict Treatment Outcomes in Advanced Cancers

    Authors: Mohamed A. Gouda, Helen J. Huang, Sarina A. Piha‐Paul, S. Greg Call, Daniel D. Karp, Siqing Fu, Aung Naing, Vivek Subbiah, Shubham Pant, Derek Dustin, Apostolia M. Tsimberidou, David S. Hong, Jordi Rodón, Funda Meric‐Bernstam, Filip Jankú - JCO Precision Oncology 2022 cited by 53